Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
Public ClinicalTrials.gov record NCT00407563. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Bevacizumab With Abraxane in Patients With Recurrent, Platinum-Resistant Primary Epithelial Ovarian or Primary Peritoneal Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer or peritoneal cancer. The study will also evaluate how the patient's quality of life is during their treatment.
Study identification
- NCT ID
- NCT00407563
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 48 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2007 (Type not available)
- Primary completion
- Feb 2011 (Actual)
- Completion
- Feb 2011 (Actual)
- Last update posted
- Apr 5, 2012
2007 – 2011
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Little Rock Hematology Oncology | Little Rock | Arkansas | 72205 | — |
| Wilshire Oncology Medical Group, Inc. | La Verne | California | 91750 | — |
| Northeast Georgia Cancer Care, LLC | Athens | Georgia | 30607 | — |
| Southeastern Gynecologic Oncology, LLC | Atlanta | Georgia | 30342 | — |
| North Idaho Cancer Center | Coeur d'Alene | Idaho | 38314 | — |
| Hematology-Oncology Centers of the Northern Rockies | Billings | Montana | 59101 | — |
| Mid-Ohio Oncology/Hematology | Columbus | Ohio | 43219 | — |
| Pennsylvania Oncology Hematology Assoc. | Philadelphia | Pennsylvania | 19106 | — |
| Chattanooga's Program in Women's Oncology | Chattanooga | Tennessee | 37403 | — |
| The West Clinic | Memphis | Tennessee | 38120 | — |
| Cancer Specialists of Tidewater, Ltd | Chesapeake | Virginia | 23320 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00407563, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2012 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00407563 live on ClinicalTrials.gov.